Pre-surgery drug and radiation for hormone-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination: a pill called elacestrant and a special type of radiation (PULSAR) given before surgery to shrink hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with stage II or III disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs (stage II or III).
- You must be at least 50 years old and post-menopausal (or a male patient).
- You need to be able to have an MRI and a biopsy of the tumor before starting treatment.
- You must be healthy enough for surgery and neoadjuvant (pre-surgery) treatment.
- Your liver, kidney, and blood counts must be within acceptable ranges.
- You cannot have had another cancer in the last 5 years, except for certain non-melanoma skin cancers or early-stage cancers that were cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.